Los Angeles, CA - (NewMediaWire) - October 18, 2021 - US Nuclear’s (OTCQB: UCLE) partner Grapheton, Inc., a pioneer in carbon-based biocompatible probes and power sources for brain-computer interfaces (BCI), today announced that Terry Lingren has been appointed Chief Executive Officer. 

Mr. Lingren joins Grapheton with a proven track record of leadership in growing technology startups from concept through market entry and high-volume manufacturing. He was the founding CEO of Resonant Inc. in 2012 and led it through its initial public offering in 2014 before retiring in 2017. Prior to Resonant, Mr. Lingren held executive and engineering positions at Qualcomm Inc. and Kyocera Wireless Corporation that led from the initial cellphone concept into dozens of products shipping millions of units per year. 

“Terry’s experience in growing highly technical startups with novel products into revenue-producing companies is exactly the emphasis we need at this juncture in Grapheton’s young life,” said Sam Kassegne, Grapheton’s Co-Founder and Chairman of the Board. “His expertise and impressive track record in nurturing companies from early concepts into high-volume products will be invaluable as we move forward with commercialization of our BCI products.”

Mr. Lingren added, “I am excited to be joining Sam and his team on what I believe are disruptive products in the BCI market. This industry is poised for growth in helping people overcome disabilities and enhance their innate capabilities, and I hope to position Grapheton firmly in this growth.”

About Grapheton, Inc.

Founded in 2019, Grapheton is an early-stage company commercializing brain probes and power sources made from glassy carbon and graphene. These probes are completely biocompatible, corrosion-resistant and nontoxic and can remain in the body for over ten years, unlike other probes which must be replaced every two years or less. Dr. Kassegne, a professor at San Diego State University who had served as Deputy Director of the National Science Foundation’s Center for Neurotechnology, has worked for over ten years with collaborators at the University of Washington and Massachusetts Institute of Technology (MIT). He and his team have three patents around the use of glassy carbon for brain probes and supercapacitors, as well as interconnecting glassy carbon with graphene. 

Contact Grapheton:

Terry Lingren

(619) 990-5728

contact@grapheton.com

www.grapheton.com

Safe Harbor Act

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com

CONTACT:

US Nuclear Corp. (OTCQB: UCLE)

Robert I. Goldstein, President, CEO, and Chairman 

Rachel Boulds, Chief Financial Officer

(818) 883 7043